Data Foundry

Drug recalls 2013

ABILIFY — Class II drug recall D-181-2013

Terminated recall by Bristol Myers Squibb Manufacturing Company, reported 2013-03-13, distributed in CA, LA, TN. CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from

Recall numberD-181-2013
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmBristol Myers Squibb Manufacturing Company, Humacao, PR, United States
Recall initiated2012-11-02
Classified2013-03-04
Reported by FDA2013-03-13
Terminated2013-05-02
DistributedCA, LA, TN
Quantity21 blister
Reason classescgmp
NDC59148-0006, 59148-0006-13, 59148-0006-92, 59148-0007, 59148-0007-13, 59148-0007-35, 59148-0007-94, 59148-0008, 59148-0008-13, 59148-0008-35, 59148-0008-95, 59148-0009, 59148-0009-13, 59148-0009-35, 59148-0009-95, 59148-0010, 59148-0010-13, 59148-0010-35, 59148-0011, 59148-0011-13, 59148-0011-35
Expiration dates2015-02-28

Product

ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka America Pharmaceutical Inc., Bristol-Myers Squibb NDC 59148-011-35

Reason for recall

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-181-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.